14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VTYX vs PHAR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas PHAR carries 36.2/100 (SELL) at $12.58 (N/M Forward P/E, 12.8% operating margin).
Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs PHAR. Trailing 12-month operating profitability (VTYX 0.0% vs PHAR 12.8%) and valuation multiples (VTYX N/M vs PHAR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $891.8M market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment74.9% of Rev ($290M)
90D Engineering Disclosures0 Published
Investor FAQ VTYX vs PHAR Key Questions & Quantitative Answers
As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas PHAR carries 36.2/100 (SELL) at $12.58 (N/M Forward P/E, 12.8% operating margin). Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).
PHAR leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PHAR at +20.8% YoY revenue growth and +74.9% YoY earnings growth on $387M TTM revenue (87.7% gross margin, 12.8% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $387M for PHAR. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus 74.9% of Rev ($290M) (0 disclosures) for PHAR.
PHAR screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PHAR trades at N/M Forward P/E, 39.4x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (14.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus PHAR (8.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, PHAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.83β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.